1. Home
  2. IONS vs AMH Comparison

IONS vs AMH Comparison

Compare IONS & AMH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

IONS

Ionis Pharmaceuticals Inc.

N/A

Current Price

$41.55

Market Cap

12.1B

Sector

Health Care

ML Signal

N/A

Logo American Homes 4 Rent of Beneficial Interest

AMH

American Homes 4 Rent of Beneficial Interest

N/A

Current Price

$32.04

Market Cap

12.0B

Sector

Real Estate

ML Signal

N/A

Company Overview

Basic Information
Metric
IONS
AMH
Founded
1989
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
12.1B
12.0B
IPO Year
1996
2012

Fundamental Metrics

Financial Performance
Metric
IONS
AMH
Price
$41.55
$32.04
Analyst Decision
Buy
Buy
Analyst Count
25
24
Target Price
★ $84.13
$36.52
AVG Volume (30 Days)
★ 2.5M
2.4M
Earning Date
11-13-2026
11-04-2026
Dividend Yield
N/A
★ 4.18%
EPS Growth
★ 21.71
9.26
EPS
N/A
★ 0.66
Revenue
N/A
★ $1,182,836,000.00
Revenue This Year
N/A
$2.92
Revenue Next Year
$47.44
$3.50
P/E Ratio
★ N/A
$47.88
Revenue Growth
N/A
★ 3.45
52 Week Low
$42.08
$27.22
52 Week High
$86.74
$35.07

Technical Indicators

Market Signals
Indicator
IONS
AMH
Relative Strength Index (RSI) 36.99 57.53
Support Level N/A $31.63
Resistance Level $46.14 $32.47
Average True Range (ATR) 1.59 0.52
MACD 0.24 0.13
Stochastic Oscillator 3.15 76.52

Price Performance

Historical Comparison
IONS
AMH

About IONS Ionis Pharmaceuticals Inc.

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).

About AMH American Homes 4 Rent of Beneficial Interest

American Homes 4 Rent is a real estate investment trust focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company's real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent's land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm's geographical markets include Dallas, Texas; Indianapolis, Indiana; Atlanta, Georgia; and Charlotte, North Carolina in terms of the number of properties in each.

Share on Social Networks: